ATE555794T1 - Heilmittel gegen hepatitis - Google Patents

Heilmittel gegen hepatitis

Info

Publication number
ATE555794T1
ATE555794T1 AT01904385T AT01904385T ATE555794T1 AT E555794 T1 ATE555794 T1 AT E555794T1 AT 01904385 T AT01904385 T AT 01904385T AT 01904385 T AT01904385 T AT 01904385T AT E555794 T1 ATE555794 T1 AT E555794T1
Authority
AT
Austria
Prior art keywords
hepatitis
remedies
virus
present
cell
Prior art date
Application number
AT01904385T
Other languages
English (en)
Inventor
Seima Itami
Tatsurou Shibui
Makoto Seki
Yoshihisa Yotsumoto
Yoshiharu Matsuura
Tatsuo Miyamura
Original Assignee
Mitsubishi Tanabe Pharma Corp
Jp Agency Of Nat Inst Of Infectious Deseases
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp, Jp Agency Of Nat Inst Of Infectious Deseases filed Critical Mitsubishi Tanabe Pharma Corp
Application granted granted Critical
Publication of ATE555794T1 publication Critical patent/ATE555794T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Steroid Compounds (AREA)
AT01904385T 2000-02-14 2001-02-13 Heilmittel gegen hepatitis ATE555794T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000034906 2000-02-14
PCT/JP2001/000967 WO2001058459A1 (en) 2000-02-14 2001-02-13 Remedies for hepatitis c

Publications (1)

Publication Number Publication Date
ATE555794T1 true ATE555794T1 (de) 2012-05-15

Family

ID=18559171

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01904385T ATE555794T1 (de) 2000-02-14 2001-02-13 Heilmittel gegen hepatitis

Country Status (8)

Country Link
US (1) US7101551B2 (de)
EP (1) EP1256348B1 (de)
KR (1) KR20020091093A (de)
CN (1) CN100391469C (de)
AT (1) ATE555794T1 (de)
AU (1) AU2001232267A1 (de)
BR (1) BR0108499A (de)
WO (1) WO2001058459A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
ATE509635T1 (de) * 2003-08-28 2011-06-15 Dainippon Sumitomo Pharma Co Mittel zur vorbeugung oder heilung entzündlicher darmerkrankungen mit anti-cd81-antikörper als aktivem inhaltsstoff
WO2005095441A1 (ja) * 2004-03-31 2005-10-13 National Institute Of Advanced Industrial Science And Technology 上皮系細胞増殖促進剤
ME02191B (me) * 2005-04-18 2016-02-20 Amgen Res Munich Gmbh Protutijela koja neutraliziraju ljudski čimbenik stimuliranja kolonija makrofaga
EP2274331B1 (de) * 2008-05-02 2013-11-06 Novartis AG Verbesserte bindemoleküle auf fibronectin-basis und ihre verwendung
ES2860453T3 (es) 2009-10-30 2021-10-05 Novartis Ag Bibliotecas universales del dominio de unión del lado inferior de la fibronectina de tipo III
CN103429265A (zh) 2010-05-25 2013-12-04 国家医疗保健研究所 用于治疗和预防hcv感染的抗包膜抗体和抗受体抗体组合物
CN103249833B (zh) * 2010-12-06 2016-06-29 大日本住友制药株式会社 人单克隆抗体
WO2013024155A1 (en) 2011-08-17 2013-02-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations of anti-hcv-entry factor antibodies and direct acting antivirals for the treatment and the prevention of hcv infection
WO2013024158A1 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
WO2013024156A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
WO2013024157A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of host targeting agents for the treatment and the prevention of hcv infection
WO2014033266A1 (en) 2012-08-31 2014-03-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-sr-bi antibodies for the inhibition of hepatitis c virus infection
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
US9833410B2 (en) 2012-10-31 2017-12-05 Takeda Gmbh Lyophilized formulation comprising GM-CSF neutralizing compound
US10745475B2 (en) 2013-08-30 2020-08-18 Takeda Gmbh Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
ES2928000T3 (es) * 2014-06-06 2022-11-14 Memorial Sloan Kettering Cancer Center Receptores de antígeno quimérico dirigidos a mesotelina y usos de los mismos
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
US11214619B2 (en) 2018-07-20 2022-01-04 Surface Oncology, Inc. Anti-CD112R compositions and methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5574132A (en) * 1991-04-05 1996-11-12 Biochem Immunosystems Inc. Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV)
EP1421951A3 (de) * 1993-05-12 2005-10-05 Chiron Corporation Konserviertes Motiv der Hepatitis C Virus E2/NS1 Region
CN1044384C (zh) * 1994-08-25 1999-07-28 中国药品生物制品检定所 抗丙型肝炎病毒抗原单克隆抗体细胞株建立及其单克隆抗体
CN1072482C (zh) * 1996-11-08 2001-10-10 山东医科大学 低分子肝素脂质体喷胶剂及制备工艺
CA2304796C (en) 1997-10-06 2013-12-03 Chiron S.P.A. Hepatitis c receptor protein cd81
WO2000005266A1 (en) * 1998-07-21 2000-02-03 Connex Gesellschaft Zur Optimierung Von Forschung Und Entwicklung Mbh Anti hepatitis c virus antibody and uses thereof
AU1462300A (en) * 1998-11-05 2000-05-22 Board Of Trustees Of The Leland Stanford Junior University Human pan-hcv human monoclonal antibodies
WO2001094571A1 (fr) 2000-06-08 2001-12-13 Mitsubishi Pharma Corporation Vecteur d'expression permettant le criblage de cellules a haute expression de proteine de recombinaison, transformant a haute expression de proteine de recombinaison, et leur utilisation

Also Published As

Publication number Publication date
US7101551B2 (en) 2006-09-05
EP1256348A4 (de) 2005-07-27
EP1256348A1 (de) 2002-11-13
KR20020091093A (ko) 2002-12-05
WO2001058459A1 (en) 2001-08-16
CN100391469C (zh) 2008-06-04
EP1256348B1 (de) 2012-05-02
AU2001232267A1 (en) 2001-08-20
US20030157132A1 (en) 2003-08-21
BR0108499A (pt) 2003-03-11
CN1423561A (zh) 2003-06-11

Similar Documents

Publication Publication Date Title
ATE555794T1 (de) Heilmittel gegen hepatitis
WO2004011478A3 (en) Anti-viral 7-deaza d-nucleosides and uses thereof
DE50102597D1 (de) Arzneimittel gegen virale erkrankungen
EA200700243A1 (ru) Способы лечения гепатита с
BRPI0415883A (pt) compostos e composições de nucleosìdeo para o tratamento de infecções virais
NO20051969L (no) Nukleosidderivater for behandling av hepatitt C virusinfeksjon.
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
GEP20104956B (en) Compounds for inhibiting hepatitis c viral replication and use thereof
WO2007001406A3 (en) Aryl-containing macrocyclic compounds
DK1169339T3 (da) Makrocykliske peptider, der inhiberer Hepatitis C-virus NS3-protease
WO2001077091A3 (en) Ns5b hcv polymerase inhibitors
EA200501689A1 (ru) Соединения в качестве ингибиторов вируса гепатита c
ECSP045300A (es) Antígenos virales
WO2009039246A3 (en) Methods of treating a flaviviridae family viral infection, compositions for treating a flaviviridae family viral infection, and screening assays for identifying compositions for treating a flaviviridae family viral infection
ID27457A (id) Komposisi untuk pengobatan hiv dan infeksi virus lainnya
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
WO2007084413A3 (en) Methods for treating hepatitis c
EA200600498A1 (ru) Макроциклические пептиды, проявляющие противовирусную активность в отношении вируса гепатита с
BR0305259A (pt) Inibidores de hcv ns5b polimerase
WO2010047830A3 (en) Agents for hcv treatment
WO2003055896A3 (en) Anti-viral 7-deaza l-nucleosides
DK1037650T3 (da) Præparater til behandling af Staphylococcus aureus-infektioner
PT1299395E (pt) Oxazinoquinolonas uteis para o tratamento de infeccoes provocadas por virus
AU7602800A (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
NO20033829L (no) Virusdrepende preparater